Dianthus Therapeutics Price Pattern Analysis
| DNTH Stock | 90.42 0.18 0.20% |
Momentum
OversoldOverbought
63 · Buy Extended
EPS Estimate Next Quarter -0.94 | EPS Estimate Current Year -4.00 | EPS Estimate Next Year -4.90 | Wall Street Target Price 126.38 | EPS Estimate Current Quarter -1.03 |
Attention data alongside price movement for Dianthus Therapeutics reveals how sensitive the stock is to headlines. Headline frequency data and corresponding price observations form the analytical foundation.
Dianthus Therapeutics Current Signal Summary
Dianthus Therapeutics's momentum reading (RSI at 0) sits in oversold territory, while the expected daily return of 1.02% is positive and hype elasticity is positive. Daily volatility at 4.26% is moderate, suggesting a standard range of near-term outcomes. Moderate headline density (9 events/month) reflects steady media coverage. Overall, signals for Dianthus Therapeutics are mixed — expected returns are positive but momentum is weak, suggesting a potential turning point.
Dianthus Therapeutics Sentiment and Price Pattern
Attention patterns around Dianthus Therapeutics are mapped against recent price behavior. Headline signals are shown alongside recent price movement for direct comparison.
When sentiment and price diverge for Dianthus Therapeutics, it often signals a potential shift ahead. Reading sentiment alongside other signals strengthens the analytical picture.
Hype signals for Dianthus Therapeutics show how market attention has shifted in recent periods. Attention shifts read alongside volatility and performance references sharpen near-term expectations.
Dianthus Therapeutics Post-Event Predicted Price | $ 94.31 |
Attention context alongside forecasting, technical signals, and analyst estimates adds depth. Earnings views and momentum indicators complement sentiment signals.
The concept of mean reversion suggests that Dianthus Therapeutics' price will eventually return toward its long-run average. Positions sized too aggressively against the trend often suffer sustained losses before reversion occurs in Dianthus Therapeutics. The mean reversion framework for Dianthus Therapeutics is built on the premise that markets are not perfectly efficient.
Post-Sentiment Price Density Analysis
The probability density for Dianthus Therapeutics shows how predicted future prices spread across the outcome range. Dianthus Therapeutics' price distribution after major news events tends to be skewed, with larger potential downside moves for established companies. This distribution for Dianthus Therapeutics incorporates Dianthus Therapeutics' historical volatility, mean reversion tendencies, and jump risk.
Next price density |
| Expected price to next headline |
Estimated Post-Sentiment Price Volatility
Using Dianthus Therapeutics' historical news impact data, we estimate the likely price corridor after a significant headline. Dianthus Therapeutics' post-sentiment downside and upside margins for the prediction period are 90.05 and 98.57, respectively. Predictive accuracy varies across different news categories and market regimes for Dianthus Therapeutics.
Current Value
The after-hype framework applied to Dianthus Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. The practical value is that it frames how far price could retrace or stabilize once the headline cycle loses intensity.
Price Outlook Analysis
Sudden rallies in Dianthus Therapeutics without backing data often point to speculative buying or fund shifts. Volume spikes in Dianthus Therapeutics without matching news often signal that momentum is driving the trades.
| Expected Return | Period Volatility | Sentiment Sensitivity | Peer Sensitivity | News Density | Peer Density | Next Expected Sentiment |
1.02 | 4.26 | 3.89 | 0.28 | 9 Events | 5 Events | In 9 days |
| Latest Traded Price | Expected Post-Event Price | Potential Return on Next Event | Post-Sentiment Volatility | |
90.42 | 94.31 | 4.30 |
|
Market Sentiment Timeline
Dianthus Therapeutics is currently traded for 90.42. Dianthus Therapeutics has a historical sentiment sensitivity of 3.89. Peers average a sentiment sensitivity of -0.28. is anticipated to increase in value after the next headline, with the post-event price near 94.31 or above. The average volatility of media hype impact on DNTH the price is about 111.81%. The price growth on the next news is projected to be 4.3%, whereas the daily expected return is currently at 1.02%. The volatility of peer sentiment impact on Dianthus Therapeutics is about 1543.48%, with the expected peer-implied price after the next announcement near 90.14. Dianthus Therapeutics generates negative cash flow from operationsGiven a 90-day horizon, the next anticipated press release will be in 9 days. Dianthus Therapeutics Basic Forecasting Models places Dianthus Therapeutics' projections alongside historical fundamentals.For more information on Dianthus Stock please use our How to Invest in Dianthus Therapeutics overview. It covers the key aspects of trading Dianthus Stock.Related Market Sentiment Analysis
Understanding how Dianthus Therapeutics' direct competitors react to news provides context for anticipating sector-wide sentiment shifts. Peer market sentiment analysis distinguishes between sector-level sentiment shifts and Dianthus Therapeutics-specific developments. News about regulatory changes, technological disruptions, or macro shifts can affect Dianthus Therapeutics' entire competitive landscape.
| SentimentElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ELVN | Enliven Therapeutics | -0.03 | 17 per month | 2.41 | 0.18 | 10.28 | -4.28 | 19.83 | |
| TSHA | Taysha Gene Therapies | -0.50 | 15 per month | 2.73 | 0.16 | 8.07 | -4.76 | 32.15 | |
| SANA | Sana Biotechnology | -0.18 | 11 per month | 0.00 | -0.06 | 8.41 | -7.71 | 21.44 | |
| ATAI | ATAI Life Sciences | -0.50 | 21 per month | 3.91 | 0.08 | 10.08 | -5.91 | 27.85 | |
| NKTR | Nektar Therapeutics | -0.50 | 12 per month | 2.45 | 0.21 | 10.27 | -5.05 | 58.13 | |
| ANAB | AnaptysBio | -0.03 | 7 per month | 2.87 | 0.26 | 13.09 | -4.26 | 26.30 | |
| OCS | Oculis Holding AG | 0.00 | 0 per month | 2.10 | 0.05 | 4.19 | -3.88 | 12.61 | |
| BBOT | BridgeBio Oncology Therapeutics | -0.50 | 18 per month | 0.00 | -0.07 | 5.42 | -6.24 | 19.68 | |
| IMTX | Immatics NV | -0.02 | 25 per month | 2.24 | 0.13 | 5.87 | -3.59 | 18.55 | |
| TRML | Tourmaline Bio | -0.50 | 29 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dianthus Therapeutics Additional Predictive Modules
Price prediction tools for Dianthus Therapeutics synthesize indicator signals with time-series patterns to model directional expectations. Forward estimates should be treated as probability-weighted scenarios rather than point predictions.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for Dianthus Therapeutics evaluates news tone, positioning, and narrative momentum. Narrative divergence can signal instability and regime transition risk. Dianthus Therapeutics has a market cap of 4.94 billion, ROE of -22.7%.
Dianthus Therapeutics analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Where analyst coverage exists, consensus estimates are factored in.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Popular Tools for Dianthus Stock analysis
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for riskETFsFind actively traded Exchange Traded Funds (ETF) from around the worldBalance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratiosPiotroski F ScoreEvaluate financial strength using the Piotroski F-Score, a nine-factor fundamental analysis modelPortfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your accountPerformance AnalysisCheck effects of mean-variance optimization against your current asset allocationPositions RatingsView algorithmic ratings for individual portfolio positions based on fundamental analysis and risk-adjusted market performancePortfolio CenterAll portfolio management and optimization tools to improve performance of your portfoliosPortfolio HoldingsCheck your current holdings and cash position to determine if your portfolio needs rebalancing